AVOS Life Sciences

Table of Contents - Lipid Modulating Agents

Disease Etiology 6
Primary Dyslipidemia 6
Secondary Dyslipidemia 6
Epidemiology & Patient Population Estimates 7
Theoretical Patient Population 7
Addressable Patient Population 7
Treated Patient Population 8
Drivers of Growth 8
Availability of Generics 8
Access for Elderly 8
Public Awareness 8
New Guidelines 8
Dyslipidemia Patient Population Model 9
U.S. Statins Market Model, 2004-2013 10
Disease & Market Definitions 10
Forecasting Methodology 10
Market Segmentation 10
Market Revenue Forecasts 11
AVOS Physician Panel Results 15
Physician Treatment Patterns 15
Patient Compliance 16
Drivers of Non-Compliance 16
Asymptomatic Prevention 16
Cost 16
Natural Treatment 16
Side Effects 16
Lack of Education 16
Physician Product Selection Criteria 17
Insurance Coverage 17
Sample Availability 17
Efficacy 17
Marketing Efforts 17
Physician Product Ratings & Forecasts of Future Market Trends 18
Market Overview 20
Leading Products 20
Market History 20
Current Market Environment 21
Future OTC Switch Unlikely 22
Product Profiles
Lipitor 23
U.S. Perspective 23
Worldwide Perspective 24
AVOS Physician Panel Discussions 24
Zetia/Vytorin 25
U.S. Perspective 25
Worldwide Perspective 26
AVOS Physician Panel Discussions 26
Product History 27
Crestor 28
U.S. Perspective 28
Worldwide Perspective 29
AVOS Physician Panel Discussions 29
Crestor Safety Controversy 30
Zocor 31
U.S. Perspective 31
Worldwide Perspective 32
AVOS Physician Panel Discussions 32
Pravachol 33
U.S. Perspective 33
Worldwide Perspective 33
AVOS Physician Panel Discussions 34
Lescol/Lescol XL 35
U.S. Perspective 35
Worldwide Perspective 35
AVOS Physician Panel Discussions 35
Tricor 36
U.S. Perspective 37
Worldwide Perspective 37
Product History 37
Patent Challenges and Reform 37
AVOS Physician Panel Discussions 37
Niaspan/Advicor 38
U.S. Perspective 38
Worldwide Perspective 39
Product History 39
AVOS Physician Panel Discussions 39
Caduet 40
U.S. Perspective 40
Worldwide Perspective 41
AVOS Physician Panel Discussions 41
Atorvastatin 42
U.S. Perspective 42
Worldwide Perspective 43
AVOS Physician Panel Discussions 43
MK-0524A/MK-0524B 44
U.S. Perspective 44
Worldwide Perspective 45
AVOS Physician Panel Discussions 45
Simcor 46
U.S. Perspective 46
Worldwide Perspective 46
AVOS Physician Panel Discussions 47
ABT-335/Crestor + ABT-335 48
U.S. Perspective 48
Worldwide Perspective 49
AVOS Physician Panel Discussions 49
TAK-475 50
U.S. Perspective 50
Worldwide Perspective 51
AVOS Physician Panel Discussions 51
Drugs in Development 52
R&D Overview 52
ACAT Inhibitors 52
Squalene Synthase Inhibitors 52
PPAR Agonists 52
CETP Inhibitors 52
Assessment of R&D Success Rates 52
Products in the Pipeline 53
Phase III (11 agents) 53
Phase II (11 agents) 54
Cover

Production date: August 2007

Order

Print Copy - $5,000

Single Site license PDF - $7,000

Global License PDF - $9,995

Contact Information:

If you wish to see sample pages or to learn more about AVOS Therapeutic Market Reports, contact Mike Goodman
919-475-9695
reports@avoslifesciences.com